InfoBionic.Ai Collaborates with Anumana to Advance AI-Based Technology for Early Detection of Cardiac Diseases
Shots:
- InfoBionic.Ai and Anumana have signed a joint research agreement for developing & commercializing AI-based remote technology to identify cardiac diseases using Anumana’s ECG-AI technology and InfoBionic.Ai’s MoMe ARC platform
- The collaboration aims at enhancing the ability of InfoBionic.Ai’s MoMe ARC Platform for earlier cardiac disease diagnosis in the remote patient monitoring setting. Both companies will work with the Mayo Clinic for the development
- As per the agreement, Anumana will combine its ECG-AI LEF algorithm with InfoBionic.Ai’s remote cardiac monitoring platform to identify LEF by remote cardiac activity monitoring. Both will confirm the clinical utility of the combined solution for regulatory approval. ECG-AI LEF's review across the EU is ongoing
Ref: InfoBionic.Ai | Image: InfoBionic.Ai
Related News:- Anumana Receives the US FDA’s Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
